Breast Cancer

, 8:63 | Cite as

Detection of Breast Cancer micrometastases in peripheral blood using immunomagnetic separation and immunocytochemistry

  • Seung Jin Kim
  • Noriko Ikeda
  • Eiichi Shiba
  • Yuki Takamura
  • Shinzaburo Noguchi
Original Article



Although there have been many reports on the immunocytochemical detection of bone marrow micrometastases in breast cancer patients, peripheral blood micrometastases (PBM) have rarely been studied by immunocytochemistry (ICC)


PBM in operable and metastatic breast cancer patients were studied using immunomagnetic separation of tumor cells followed by immunocytochemistry (IMS-ICC)


PBM were not detected in any peripheral blood samples from 21 healthy women, six patients with benign disease, or in a 21 patients with primary operable breast cancer, of which there were 7 stage I (n=7), 9 stage II, 2 stage III, and 3 inflammatory tumors. On the other hand, PBM were detected in 8 of 29 patients with metastatic breast cancers (27.6%). The number of tumor cells per patient varied from 2 to 90 cancer cells (median: 8 cells). Positivity of PBM was not significantly associated with the first site of recurrence, number of involved organs, tumor marker status, performance status, or disease-free interval, but it was significantly (p<0.01) associated with progesterone receptor negativity


PBM are very rare in primary operable breast cancer patients but can be observed in a considerable number of metastatic breast cancer patients. The clinical significance of PBM still remains to be established.

Key words

Micrometastases Peripheral blood Immunomagnetic separation Immunocytochemistry Breast cancer 


  1. 1).
    Pelkey TJ, Frierson Jr HF, Bruns DE: Molecular and immunological detection of circulating tumor cells and micrometastases from solid tumors.Clin Chem 42:1369–1381, 1996.PubMedGoogle Scholar
  2. 2).
    Funke I, Schraut W: Meta-analyses of studies on bone marrow micrometastases: an independent prognostic impact remains to be substantiated.J Clin Oncol 16:557–566, 1998.PubMedGoogle Scholar
  3. 3).
    Braun S, Pantel K: Micrometastatic bone marrow involvement: detection and prognostic significance.Medical Oncology 16:154–165, 1999.PubMedCrossRefGoogle Scholar
  4. 4).
    Cote RJ, Rosen PP, Lesser ML,et al: Prediction of early relapse in patients with operable breast cancer by detection of occult bone marrow micrometastases.J Clin Oncol 9:1749–1756, 1991.PubMedGoogle Scholar
  5. 5).
    Pantel K, Schlimok G, Braun S,et al: Differential expression of proliferation-associated molecules in individual micrometastatic carcinoma cells.J Natl Cancer Inst 85:1419–1424, 1993.PubMedCrossRefGoogle Scholar
  6. 6).
    Braun S, Muller M, Hepp F,et al: Micrometastatic breast cancer cells in bone marrow at primary surgery: Prognostic value in comparison with nodal status.J Natl Cancer Inst 90:1099–1101, 1998.PubMedCrossRefGoogle Scholar
  7. 7).
    Braun S, Pantel K, Muller M,et al: Cytokeratin-posi-tive cells in the bone marrow and survival of patients with stage I, II, or III breast cancer.N Engl J Med 342:525–533, 2000.PubMedCrossRefGoogle Scholar
  8. 8).
    Mansi JL, Gogas H, Bliss JM,et al: Outcome of primary-breast-cancer patients with micrometastases: a longterm follow-up study.Lancet 354:197–202, 1999.PubMedCrossRefGoogle Scholar
  9. 9).
    Dearnaley DP, Ormerod MG, Sloane JP: Micrometastases in breast cancer: longterm follow-up of the first patient cohort.Eur J Cancer 27:236–239, 1991.PubMedCrossRefGoogle Scholar
  10. 10).
    Mansi JL, Easton D, Berger U,et al: Bone marrow micrometastases in primary breast cancer: prognostic significance after 6 years’ follow-up.Eur J Cancer 27:1552–1555, 1991.PubMedGoogle Scholar
  11. 11).
    Berger U, Bettelheim R, Mansi JL,et al: The relationship between micrometastases in the bone marrow, histopathologic features of the primary tumor in breast cancer and prognosis.Am J Clin Pathol 90:1–6, 1988.PubMedGoogle Scholar
  12. 12).
    Diel IJ, Kaufmann M, Costa SD,et al: Micrometastatic breast cancer cells in bone marrow at primary surgery: prognostic value in comparison with nodal status.J Natl Cancer Inst 88:1652–1664, 1996.PubMedCrossRefGoogle Scholar
  13. 13).
    Solomayer E-F, Diel IJ, Wallwiener D,et al: Prognostic relevance of urokinase plasminogen activator detection in micrometastatic cells in the bone marrow of patients with primary breast cancer.Br J Cancer 76:812–818, 1997.PubMedGoogle Scholar
  14. 14).
    Molino A, Pelosi G, Turazza M,et al: Bone marrow micrometastases in 109 breast cancer patients: correlations with clinical and pathological features and prognosis.Breast Cancer Res Treat 42:23–30, 1997.PubMedCrossRefGoogle Scholar
  15. 15).
    Pantel K, Schlimok G, Angstwurm M,et al: Methodological analysis of immunocytochemical screening for disseminated epithelial tumor cells in bone mar- row.JHematother 3:165–173, 1994.Google Scholar
  16. 16).
    Kruger W, Krzizanowski C, Holweg M,et al: Reverse transcriptase/polymerase chain reaction detection of cytokeratin-19 mRNA in bone marrow and blood of breast cancer patients.J Cancer Res Clin Oncol 122:679–686, 1996.PubMedCrossRefGoogle Scholar
  17. 17).
    Bostick PJ, Chatterjee S, Chi DD,et al: Limitation of specific reverse-transcriptase polymerase chain reaction markers in the detection of metastases in the lymph nodes and blood of breast cancer patients.J Clin Oncol 16:2632–2640, 1998.PubMedGoogle Scholar
  18. 18).
    Schoenfeld A, Kruger KH, Gomm J,et al: The detection of micrometastases in the peripheral blood and bone marrow of patients with breast cancer using immunohistochemistry and reverse transcriptase polymerase chain reaction for keratin 19.Eur J Cancer 33:854–861, 1997.PubMedCrossRefGoogle Scholar
  19. 19).
    Vannucchi AM, Bosi A, Glinz S,et al: Evaluation of breast tumor cell contamination in the bone marrow and leukapheresis collections by RT-PCR for cytokeratin-19 mRNA.Br J Haemat 103:610–617, 1998.CrossRefGoogle Scholar
  20. 20).
    Slade MJ, Smith BM, Sinnett HD,et al: Quantitative polymerase chain reaction for the detection of micrometastases in patients with breast cancer.J Clin Oncol 17:870–879, 1999.PubMedGoogle Scholar
  21. 21).
    Gerhard M, Juhl H, Kalthoff H,et al: Specific detection of carcinoembryonic antigen-expressing tumor cells in bone marrow aspirates by polymerase chain reaction.JClin Oncol 12:725–729, 1994.Google Scholar
  22. 22).
    Ghossein RA, Bhattacharya S, Rosai J: Molecular detection of micrometastases and circulating tumor cells in solid tumors. Clin Cancer Res 5:1950–1960, 1999.PubMedGoogle Scholar
  23. 23).
    Raj GV, Moreno JG, Gomella LG: Utilization of polymerase chain reaction technology in the detection of solid tumors.Cancer 82:1419–1442, 1998.PubMedCrossRefGoogle Scholar
  24. 24).
    Janni W, Gastroph S, Hepp F,et al: Prognostic significance of an increased number of micrometastatic tumor cells in the bone marrow of patients with first recurrence of breast carcinoma.Cancer 88:2252–2259, 2000.PubMedCrossRefGoogle Scholar
  25. 25).
    Hermanek P: Disseminated tumor cells versus micrometastasis: definitions and problems.Anticancer Res 19:2771–2777, 1999.PubMedGoogle Scholar
  26. 26).
    Naume B, Borgen E, Beiske K,et al: Immunomagnetic techniques for the enrichment and detection of isolated breast carcinoma cells in bone marrow and peripheral blood.J Hematother 6:103–114, 1997.PubMedGoogle Scholar
  27. 27).
    Kremens B, Wieland R, Reuss R: Enrichment of residual tumor cells in bone marrow or peripheral blood cells in a neuroectodermal tumor model.Pediatr Hematol Oncol 11:625–631, 1994.PubMedCrossRefGoogle Scholar
  28. 28).
    Griwatz C, Brandt B, Assmann G,et al: An immunological enrichment method for epithelial cells from peripheral blood.J Immunol Methods 183:251–265, 1995.PubMedCrossRefGoogle Scholar
  29. 29).
    Soria JC, Gauthier LR, Raymond E,et al: Molecular detection of telomerase-positive circulating epithelial cells in metastatic breast cancer patients.Clin Cancer Res 5:971–975, 1999.PubMedGoogle Scholar
  30. 30).
    Zhong XY, Kaul S, Lin YS,et al: Sensitive detection of micrometastases in bone marrow from patients with breast cancer using immunomagnetic isolation of tumor cells in combination with reverse transcriptase/polymerase chain reaction for cytokeratin-19.J Cancer Res Clin Oncol 126:212–218, 2000.PubMedCrossRefGoogle Scholar
  31. 31).
    Watne AL, Sandberg AA, Moore GE: The prognostic value of tumor cells in the blood.Arch Surg 83:190–195, 1961.PubMedGoogle Scholar
  32. 32).
    Engell HC: Cancer cells in the blood. A five to nine year follow up study.Ann Surg 149:457–461, 1959.PubMedCrossRefGoogle Scholar
  33. 33).
    Landell NE, Silvan A, Zajicek J: Atypical cells in peripheral blood in 100 cases of mammary carcinoma and 100 controls.Acta Cytol 7:91–96, 1963.PubMedGoogle Scholar
  34. 34).
    Moore GE, Sandberg AA: Clinical aspects of cancer cells in the blood.Acta Cytol 9:175–184, 1957.Google Scholar
  35. 35).
    Fleming JA: Tumor cells in the blood in carcinoma of the breast.Proc Roy Soc Med 56:497–500, 1963.PubMedGoogle Scholar
  36. 36).
    Smith BM, Slade MJ, English J,et al: Response of circulating tumor cells to systemic therapy in patients with metastatic breast cancer: comparison of quantitative polymerase chain reaction and immunocyto- chemical techniques.J Clin Oncol 18:1432–1439, 2000.PubMedGoogle Scholar
  37. 37).
    Datta HY, Adams PT, Drobyski WR,et al: Sensitive detection of occult breast cancer by the reverse-tran-scriptase polymerase chain reaction.J Clin Oncol 12:475–482, 1994.PubMedGoogle Scholar
  38. 38).
    Mori M, Mimori K, Ueo H,et al: Molecular detection of circulating solid carcinoma cells in the peripheral blood: the concept of early systemic disease.Int J Cancer 68:739–743, 1996.PubMedCrossRefGoogle Scholar
  39. 39).
    Brandt B, Roetger A, Heidi S: Isolation of blood-borne epithelium-derived c-erbB-2 oncoprotein-positive clustered cells from the peripheral blood of breast cancer patients.Int J Cancer 76:824–828, 1998.PubMedCrossRefGoogle Scholar
  40. 40).
    Singletary SE, Larry L, Trucker SL,et al: Detection of micrometastatic tumor cells in bone marrow of breast carcinoma patients.J Surg Oncol 47:32–36, 1991.PubMedCrossRefGoogle Scholar
  41. 41).
    Schlimok G, Pantel K, Loibner H,et al: Reduction of metastatic carcinoma cells in bone marrow by intravenously administered monoclonal antibody: Towards a novel surrogate test to monitor adjuvant therapies of solid tumours.Eur J Cancer 31A:1799–1803, 1995.PubMedCrossRefGoogle Scholar
  42. 42).
    Allgayer H, Heiss MM, Riesenberg R,et al: Urokinase plasminogen activator receptor (uPA-R): one potential characteristic of metastatic phenotypes in minimal residual tumor disease.Cancer Res 57:1394–1399, 1997.PubMedGoogle Scholar

Copyright information

© The Japanese Breast Cancer Society 2001

Authors and Affiliations

  • Seung Jin Kim
    • 1
  • Noriko Ikeda
    • 1
  • Eiichi Shiba
    • 1
  • Yuki Takamura
    • 1
  • Shinzaburo Noguchi
    • 1
  1. 1.Department of Surgical OncologyOsaka University Medical SchoolJapan

Personalised recommendations